GenMark Diagnostics (GNMK) Insider Sells $37,721.69 in Stock

GenMark Diagnostics (NASDAQ:GNMK) insider Hany Massarany sold 5,459 shares of the stock in a transaction dated Monday, May 21st. The stock was sold at an average price of $6.91, for a total value of $37,721.69. Following the sale, the insider now directly owns 698,376 shares in the company, valued at $4,825,778.16. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Hany Massarany also recently made the following trade(s):

  • On Wednesday, May 23rd, Hany Massarany sold 4,168 shares of GenMark Diagnostics stock. The stock was sold at an average price of $6.88, for a total value of $28,675.84.
  • On Wednesday, May 2nd, Hany Massarany sold 1,055 shares of GenMark Diagnostics stock. The stock was sold at an average price of $6.18, for a total value of $6,519.90.
  • On Monday, February 26th, Hany Massarany sold 17,300 shares of GenMark Diagnostics stock. The stock was sold at an average price of $4.17, for a total value of $72,141.00.

Shares of NASDAQ:GNMK traded down $0.08 during trading on Friday, reaching $6.92. 4,286 shares of the company’s stock traded hands, compared to its average volume of 340,623. GenMark Diagnostics has a fifty-two week low of $3.63 and a fifty-two week high of $13.50. The company has a quick ratio of 2.45, a current ratio of 2.79 and a debt-to-equity ratio of 0.24. The stock has a market capitalization of $384.56 million, a PE ratio of -5.84 and a beta of 0.55.

GenMark Diagnostics (NASDAQ:GNMK) last posted its earnings results on Tuesday, May 1st. The medical equipment provider reported ($0.21) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.22) by $0.01. GenMark Diagnostics had a negative return on equity of 77.35% and a negative net margin of 97.90%. The firm had revenue of $20.65 million for the quarter, compared to analysts’ expectations of $17.12 million. sell-side analysts expect that GenMark Diagnostics will post -0.77 earnings per share for the current fiscal year.

GNMK has been the topic of several analyst reports. BidaskClub raised GenMark Diagnostics from a “hold” rating to a “buy” rating in a research report on Tuesday, March 27th. Zacks Investment Research raised GenMark Diagnostics from a “sell” rating to a “hold” rating in a research report on Thursday, January 25th. BTIG Research set a $11.00 price target on GenMark Diagnostics and gave the stock a “buy” rating in a research report on Wednesday, May 2nd. Canaccord Genuity cut their price target on GenMark Diagnostics from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, February 28th. Finally, Needham & Company LLC restated a “buy” rating and set a $11.00 target price on shares of GenMark Diagnostics in a research report on Tuesday, April 24th. Three analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $10.60.

Large investors have recently bought and sold shares of the company. Two Sigma Investments LP grew its position in shares of GenMark Diagnostics by 2,266.9% during the 4th quarter. Two Sigma Investments LP now owns 435,887 shares of the medical equipment provider’s stock valued at $1,818,000 after acquiring an additional 417,471 shares during the period. Granite Investment Partners LLC grew its position in shares of GenMark Diagnostics by 153.6% during the 4th quarter. Granite Investment Partners LLC now owns 215,760 shares of the medical equipment provider’s stock valued at $900,000 after acquiring an additional 130,677 shares during the period. UBS Asset Management Americas Inc. grew its position in shares of GenMark Diagnostics by 111.1% during the 4th quarter. UBS Asset Management Americas Inc. now owns 49,400 shares of the medical equipment provider’s stock valued at $206,000 after acquiring an additional 26,000 shares during the period. Penn Capital Management Co. Inc. lifted its stake in GenMark Diagnostics by 56.4% in the 4th quarter. Penn Capital Management Co. Inc. now owns 543,715 shares of the medical equipment provider’s stock valued at $2,267,000 after buying an additional 196,150 shares in the last quarter. Finally, Fairpointe Capital LLC purchased a new position in GenMark Diagnostics in the 4th quarter valued at about $220,000.

GenMark Diagnostics Company Profile

GenMark Diagnostics, Inc, a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor detection technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results.

Insider Buying and Selling by Quarter for GenMark Diagnostics (NASDAQ:GNMK)

Receive News & Ratings for GenMark Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply